Managing the adverse effects of interferon-β therapy in multiple sclerosis
Managing the adverse effects of interferon-β therapy in multiple sclerosis
复制标题
DOI：
10.2165/00002018-200022020-00006
复制
发表时间：
2000-02-01
期刊：
影响因子：
4.2
通讯作者：
Rieckmann, P
中科院分区：
文献类型：
--
作者：
Bayas, A;Rieckmann, P
干扰素-β是复发缓解型多发性硬化症的既定疗法。最近，它也已被证明，干扰素β-1b是有效的继发进展型多发性硬化症。然而，干扰素-β治疗的副作用是常见的，特别是在治疗的第一周，并且是一个主要问题。流感样症状、注射部位反应和实验室异常是最常见的不良反应，可能导致许多患者依从性降低甚至停止治疗。因此，努力尽量减少这些反应，例如，适当的comedication与镇痛/解热药物，使用正确的制备和注射技术，有时修改干扰素β的剂量，是相当重要的。本文提供了一个概述的管理与干扰素β治疗相关的临床相关的不良反应，根据文献综述和个人经验。患者信息的重要方面也得到了强调。如果遵循这些建议，大多数患者与干扰素-β相关的不良反应可能会大大减少。
Interferon-beta is an established therapy in relapsing-remitting multiple sclerosis. Recently, it has also been shown that interferon-beta-1b is effective in secondary progressive multiple sclerosis. However, adverse effects of interferon-beta treatment are common, particularly during the first weeks of treatment, and are a major concern. Flu-like symptoms, injection site reactions and laboratory abnormalities are the most common adverse effects, and may result in reduced compliance or even discontinuation of treatment in a number of patients. Therefore, efforts to minimise these reactions, e.g. appropriate comedication with analgesic/antipyretic drugs, use of correct preparation and injection technique and sometimes modification of the dosage of interferon-beta, are of considerable importance.This article provides an overview of the management of clinically relevant adverse effects related to treatment with interferon-beta, based on a literature review and personal experience. Essential aspects of patient information are also stressed. If these recommendations are followed, adverse effects related to interferon-beta may be substantially reduced in the majority of patients.